Abstract Purpose: CD99 is a cell adhesion molecule associated with human tumors. The aim of the present study was to characterize its role in the development and progression of human gastric adenocarcinoma. Experimental Design: The expression of CD99 was investigated in 283 gastric adenocarcinomas and related lesions and 9 gastric carcinoma cell lines.We also analyzed the methylation status of CD99 gene by using methylation-specific PCR and examined loss of heterozygosity (LOH) of this gene locus by using an intragenic marker. Moreover, we assessed whether SP1, a positive transcription factor for CD99, is expressed in these samples. Results: We found that the decreased expression of CD99 was strongly associated with poor survival and unfavorable clinicopathologic variables. Promoter region methylation (15 of 89, 16.9%) and LOH (21 of 74, 28.4%) were observed and significantly associated with CD99 down-regulation (P < 0.05). In addition, most of the gastric adenocarcinoma cases with CD99 down-regulation had reduced expression of SP1 (47 of 103, 45.6%; P < 0.01). This relationship between CD99 and SP1was consolidated by using SP1small interfering RNA transfection experiment and CD99 promoter luciferase assay. Furthermore, we showed that CD99 down-regulation was associated with proliferation and migration in gastric carcinoma cell line. Conclusion: These observations suggest that CD99 down-regulation is a critical event in the progression of gastric adenocarcinoma, and CD99 promoter methylation, CD99 LOH, and SP1 down-regulation were responsible for the down-regulation of CD99.
Gastric carcinoma is the second leading cause of cancer mortality in the world (1) . A number of cell adhesion molecules have been examined as potential clinical biomarkers of gastric adenocarcinoma, including CDH1 (E-cadherin), FXYD5 (dysadherin), TACSTD1 (Ep-CAM), and the CD44 splicing variants CD44v6 and CD44v9 (2 -6) . A germline mutation in CDH1 has been frequently observed in hereditary gastric carcinoma, and multivariate analyses have revealed that CDH1 down-regulation is an independent prognostic factor for gastric cancer (7) . In addition, increased expression of FXYD5, a CDH1 inactivator, has been significantly associated with poor prognosis (8, 9) . TACSTD1 down-regulation and CD44v6 upregulation have been also suggested to be prognostic markers for gastric cancer (5, 6) .
Another interesting adhesion molecule is CD99, which is a sialomucin-type glycoprotein that is ubiquitously expressed, albeit to varying degrees, by different cell types (10) . Although its function and signaling pathway are not fully understood, it is known that CD99 is involved in a number of cellular events such as cell-cell adhesion (11, 12) , maintenance of cellular morphology (13) , and cell death (14, 15) . CD99 also regulates the adhesion and diapedesis of leukocytes to inflamed vascular endothelium (16) . Recently, it was proposed that CD99 downregulation, induced by the EBV-encoded latent membrane protein-1, in B cells is involved in the pathogenesis of Hodgkin's disease (17) . Furthermore, the increased or decreased expression of CD99 has been also suggested to act as a marker of various kinds of tumors, including Ewing's sarcoma/ primitive neuroectodermal tumor (18) , lymphoblastic lymphoma/leukemia (19) , some rhabdomyosarcomas (20) , granulose cell tumor and sertoli-leydig cell tumor of the ovary (21) , pancreatic endocrine tumors (22) , gallbladder carcinoma (23) , and stomach carcinoma (24) . Based on these previous reports, we speculated that altered CD99 expression could also be a prognostic marker for gastric carcinoma patients.
In the present study, we examined the expression of CD99 by normal gastric samples, gastric carcinomas, and other gastric lesions by using immunohistochemistry-based tissue microarray analysis and explored the clinical significance of CD99 down-regulation in gastric adenocarcinoma. In addition, we evaluated the mechanism by which CD99 becomes downregulated in gastric carcinoma by assessing the methylation status of the CD99 promoter, loss of heterozygosity (LOH) at the CD99 gene locus, and expression of SP1, which is a transcription factor that induces CD99 expression. Furthermore, we showed the pathophysiologic role of CD99 downregulation in gastric carcinoma.
Materials and Methods
Patients, tissue samples, immunohistochemistry, and evaluation of results. Tissues from patients with gastric carcinoma and the other gastric lesions, consisting of 114 gastric carcinomas, 20 high-grade dysplasias, 17 low-grade dysplasias, 48 intestinal metaplasias, 30 chronic atrophic gastritis, and 54 normal gastric epithelium, were used for tissue microarray construction as previously described (25) . Ethics committee permission for this study was obtained from the institutional review board of Chungbuk National University Hospital. Immunostaining of CD99 and SP1 was done on consecutive sections, using two anti-CD99 monoclonal antibodies (clones DN16 and YG32; DiNonA) and rabbit polyclonal anti-SP1 antibody (Santa Cruz Biotechnology, Inc.). The evaluation of both the intensity of immunohistochemical staining and the proportion of positively stained epithelial cells was done as previously described (25) . A detailed description of the analysis is provided in Supplementary Materials and Methods.
Methylation-specific PCR and LOH assay. Genomic DNA extraction from the tissues microdissected from slides, normal lymphocytes, and gastric cancer cells; bisulfate treatment of DNA; and methylationspecific PCR were done as previously described (25, 26) . DNA from normal lymphocytes methylated in vitro with SssI methylase was used as the positive control, and both water blanks and PCR mixtures without template were used as negative controls. All methylated and representative unmethylated PCR fragments were sequenced (for detail, see Supplementary Materials and Methods). Primers and PCR conditions used are also provided in Supplementary Table S1 . Briefly, we designed two primer sets [i.e., (A) primers that amplify an area in the promoter region (-273 bp to -57 bp from the transcription initiation site) and (B) primers that amplify an area that is downstream of the transcription initiation site (-105 bp to +106 bp)].
LOH was assessed by subjecting tumor and normal DNA to PCR amplification of DYS403, which is a microsatellite locus that is located between exons 1 and 2 of the CD99 gene on the short arm of chromosomes Xp22.3 and Yp11.3.
7 PCR amplification and analysis were done as previously described (for detail, see Supplementary Materials and Methods; ref. 27) .
Cell lines, Western blotting, and flow cytometric analysis. Nine human stomach cancer cell lines (i.e., SNU5, SNU16, SNU216, SNU484, SNU638, MKN28, MKN74, KATOIII, and AGS) were maintained. Western blotting was done by using primary antibodies against CD99 and SP1 and ACTB (see Supplementary Materials and Methods), and CD99 and SP1 expression were semiquantified by scanning densitometry with ACTB normalization. For flow cytometric analysis, 10 6 cells were incubated with FITC-conjugated CD99 (YG32) for 20 min at 4jC, washed three times with cold PBS, fixed with 1% paraformaldehyde, and analyzed on a FACSCalibur (BDIS) by using the CellQuest software (BDIS).
Luciferase assay. CD99 promoter (-1641/+123) reporter and SP1 expression constructs were gifts from Dr. I.S. Lee SP1 and CD99 small interfering RNA transfection and real-time reverse transcription-PCR. The sense sequences of SP1 small interfering RNA (siRNA; Santa Cruz Biotechnology), CD99 type I -specific siRNA, and green fluorescent protein siRNA (control) are 5 ¶-AAUGA-GAACAGCAACAACUCC-3 ¶, 5 ¶-GAAAGGCTGGCCATTATTA-3 ¶, and 5 ¶-GGCUACGUCCAGGAGCGCACC-3 ¶, respectively. Transfections were done according to standard procedures (see Supplementary Materials and Methods). Real-time quantitative reverse transcription-PCR was carried out using the LightCycler Real-time PCR Detection system (Roche Diagnostics). PCR primers for amplifying CD99 (Type I) and the control gene hypoxanthine-guanine phosphoribosyl transferase (HPRT) are shown in Supplementary Table S1 . CD99 (Type I) and HPRT were detected in the same tube at 530 and 705 nm by using FAM-conjugated Universal Probe Library probe 21 and DYXL-labeled HPRT probe (TIB MOLBIOL GmbH) as the Taqman probe, respectively.
Establishment of CD99-overexpressing stable cell line and migration assay. CD99 and empty vector were transfected into SNU216, SNU484, KATOIII, and AGS by using a LipofectAMINE LTX (Invitrogen). Transfected cells were passaged after 1 day and selected with 400 Ag/mL G418 for 10 days. AGS and SNU484 were just established into CD99-overexpressing stable lines. Cell migration assay was done using established stable cell lines according to standard procedures (see Supplementary Materials and Methods).
Statistical analysis. Means were compared by the nonparametric methods Wilcoxon's rank sum test and Kruskal-Wallis test. The association of the expression rate with clinicopathologic factors was assessed by Fisher's exact test and Pearson's m 2 test. Kaplan-Meier analyses were done for the survival times of gastric adenocarcinoma patients. Log-rank tests were used to compare the survival curves between groups. The contribution of each mechanism to protein downregulation was determined by using the logistic regression model. Accuracy with which each mechanism predicts protein down-regulation was provided in Supplementary Materials and Methods. P < 0.05 was regarded statistically significant. All statistical analyses were done by using SPSS software (SPSS).
Results
Expression of CD99 by gastric carcinoma and other gastric lesions. The expression of CD99 by gastric adenocarcinoma and other gastric lesions was determined by immunohistochemical analysis. In normal gastric epithelia, CD99 expression was strongest around the mucus neck cells and decreases gradually as these cells differentiate into mucus and glandular cells (Supplementary Figure S1A) . Notably, CD99 was constitutively expressed at the basolateral border of epithelial cells (Supplementary Figure S1B) . CD99 expression was found to be significantly decreased in the gastric carcinoma and intestinal metaplasia samples in terms of both the average immunoreactive score and the expression rate ( Fig. 1A ; Supplementary  Fig. S2 ). Comparing with normal gastric epithelia, there is no significant change in low-grade dysplasia and high-grade dysplasia, but a slightly decease in early gastric cancer and an obvious decrease in advanced gastric cancer ( Fig. 1A ; Supplementary Table S2 ). Only 34.5% (39 of 113) of the carcinoma cases showed CD99 expression, whereas almost 90% of the normal gastric mucosa, chronic atrophic gastritis, and dysplasia Down-regulation of CD99 in gastric carcinoma is associated with unfavorable clinicopathologic variables and poor prognosis. How CD99 expression in gastric carcinoma relates to various clinicopathologic variables was analyzed. Reduced expression of CD99 was significantly associated with all unfavorable variables, including greater tumor size, nodal metastasis, advanced gastric cancer, diffuse type, poor differentiation (high grade), deep tumor invasion, and advanced clinical staging (tumor-node-metastasis staging; Fig. 1B and C; Supplementary Table S2 ). These findings were observed for both the expression rate and the average immunoreactive score.
Kaplan-Meier survival analysis revealed that, like other unfavorable prognostic factors, reduced CD99 expression was significantly associated with decreased 1-year and 3-year overall survival (P < 0.01; Table 1 ). The mean survival time was 60.1 months for CD99 -gastric carcinoma patients (74 cases) and 81.0 months for CD99 + patients (39 cases; P < 0.01). Analysis of the overall survival showed that the presence of CD99 expression was significantly associated with better prognosis (risk ratio, 0.313; P < 0.01). Moreover, Kaplan-Meier survival analysis that was separately done for the early-stage (I and II) and advanced stage (III and IV) groups showed that the absence of CD99 expression was significantly associated with shorter survival times in advanced stage patients (P < 0.05; Fig. 1D) .
Hypermethylation of the CD99 promoter region and LOH of the CD99 gene locus is associated with CD99 down-regulation. To elucidate the mechanism by which CD99 is down-regulated in gastric carcinoma, we explored the methylation status of the CD99 promoter region by using methylation-specific PCR and LOH of the CD99 gene locus. When the (A) primers were employed, methylation was found in 15 of the 89 cases of gastric cancer (16.9%; Fig. 2A-C) , and a significant correlation between promoter methylation and the absence of CD99 expression was observed (P < 0.05; Tables 1 and 2 ). In contrast, when the (B) primers were used, methylation was rarely detected (4 of 68, 5.9%), and no significant association with CD99 down-regulation was found (Tables 1 and 2 ). In addition, methylation in the promoter was associated with decreased 1-year/3-year survival (P < 0.01; Table 1 ), whereas methylation in the downstream region showed no such correlation. Despite these clinicopathologic implications of CD99 promoter methylation, we could not detect similar LOH of the CD99 gene locus was found in 21 of 74 cases (28.4%) and was significantly associated with down-regulation of CD99 expression (P < 0.05; Table 2 ). In addition, LOH of the CD99 gene locus was associated with decreased 1-year/3-year survival (P < 0.05; Table 1 ). Analysis of nine cell lines revealed that SNU638 and AGS also showed LOH of the CD99 gene locus (data not shown).
SP1 expression in gastric carcinoma was associated with CD99 expression. Whether CD99 down-regulation in stomach carcinoma is due to altered expression of SP1 was assessed by immunohistochemical analysis because the promoter region of CD99 contains several SP1-binding sites ( Fig. 2A; refs. 28, 29) . Down-regulation of SP1 in gastric carcinoma was found in 47 of 113 cases (41.6%) and was significantly associated with the down-regulation of CD99 expression (P < 0.05; Table 2 ). However, decreased expression of SP1 was not associated with decreased 1-year/3-year survival (Table 1) .
When the protein expression of CD99 and SP1 were semiquantified, the SNU5, SNU16, MKN28, and MKN74 cell lines showed high expression of both CD99 and SP1 (Fig. 3A  and B) . However, the amount of CD99 transcript in SNU484, SNU216, KATOIII, and AGS did not correlate with the protein expression of Sp1 (Fig. 3B) . When CD99 promoter assay was done, the discrepancy of SP1 and CD99 observed in SNU484 and KATOIII could be explained. In the case of SNU484, CD99 promoter was activated by itself, and SP1 inhibited CD99 promoter activity (Fig. 3C) . On the other hand, CD99 promoter was not activated by Sp1 in KATOIII (Fig. 3C) . In SNU638, MKN74, and AGS, SP1 activated CD99 promoter (Fig. 3C) . Furthermore, when SP1 siRNA was introduced into in the high CD99-and SP1-expressing line MKN74, SP1 siRNA dramatically down-regulated CD99 transcription (Fig. 3D-F) .
CD99 down-regulation was associated with proliferation and migration in gastric carcinoma cell line. CD99-overexpressing AGS stable cell line showed reduced migration and cell proliferation (Fig. 3G-I ). In accordance with, CD99 knockdown in MKN74 increased migration ( Fig. 3J and K) . However, apoptosis was not induced in transiently CD99-transfected KATOIII (data not shown). These results showed that CD99 may have essential role in migration and proliferation in gastric carcinoma.
Contribution of SP1 down-regulation, LOH, and promoter methylation to CD99 down-regulation in gastric adenocarcinoma. To assess the effect of promoter methylation, LOH, and SP1 down-regulation on CD99 expression, we did multivariate logistic regression analysis using these variables. We found that all variables were significantly associated with CD99 expression (Table 2) . Notably, promoter methylation and CD99 LOH showed high odds ratio for CD99 down-regulation (Table 2 ). These changes were not observed in most of cases without showing CD99 down-regulation (1 of 28, specificity = 96.4% for promoter methylation and 2 of 22, specificity = 96.4% for CD99 LOH), suggesting that these mechanisms are specifically related to CD99 down-regulation (Supplementary Materials and Methods). In addition, SP1 down-regulation were responsible for more cases showing CD99 downregulation than methylation and LOH (Supplementary Materials and Methods). Furthermore, decreased expression of SP1, CD99 LOH, and CD99 promoter methylation can together predict about 81% of the gastric carcinoma cases with CD99 down-regulation, suggesting that these constitute the major mechanism of inducing it (Supplementary Materials and Methods).
Discussion
Here, we studied the expression of CD99 in gastric carcinoma samples and determined its clinical significance, particularly with regard to the prognosis of the patients. We found that the expression of CD99 was clearly down-regulated in gastric carcinoma, particularly for advanced stage (P < 0.001). In addition, the loss of CD99 expression was strongly associated with a poor prognosis (P < 0.001). We also analyzed the potential mechanisms that could be responsible for CD99 down-regulation in gastric carcinoma and found that methylation of the CD99 promoter and CD99 LOH can account for the cases with CD99 down-regulation. One of supporting evidence for this is our observation that the SNU638 cell line, which shows CD99 LOH, also expresses CD99 at low levels. Finally, we found that loss of SP1 expression, which is a potent positive regulator of CD99, accounts for many of the CD99 -gastric carcinoma cases. This was revealed by immunohistochemical analysis, CD99 promoter assay, and an in vitro siRNA transfection study.
Although CD99 has been suggested to participate in various physiologic processes, its exact functions, particularly those in epithelial cells, remain unclear. Unlike lymphoid cells, epithelial cells have been rarely reported to express CD99. Here, we found that in normal gastric epithelia, CD99 is constitutively expressed at their basolateral border. The location and expression pattern of CD99 and its down-regulation in gastric carcinoma progression suggest that this molecule could act as an intercellular adhesion molecule. The role of CD99 as an intercellular adhesion molecule has already been previously Fig. 2 . Methylation status of the CD99 promoter region and LOH status of CD99 in gastric carcinoma. A, schematic depiction of the region of the CD99 gene between -400 and +200 bp relative to the transcription start site. Brown arrows, primary PCR primers; black arrows, secondary PCR primers; purple arrows, SP1-binding sites; black circles, CpGs. B, methylation-specific PCR (MSPCR) of the CD99 promoter in representative gastric carcinoma cases. U, nonmethylated; M, methylated; PC, positive control; DW, distilled water. Methylation-specific PCR was done by using sequences upstream (A) and downstream (B) of the transcription start site. C, representative sequences of the methylation-specific PCR (A) and (B) products. Arrows, unmethylated and methylated sites. Although the sequence from the unmethylated DNA sample shows the C-to-Tconversion (arrows), the corresponding sequence of the methylated case shows the retention of Cs (arrows). D, schematic depiction of the CD99 gene locus showing the location of the microsatellite marker DYS403. E, representative results after assessing normal gastric muscosa (N) and tumor specimens (T) from two gastric carcinoma patients. Arrow, LOH. (11, 12) . Moreover, upon CD99 stimulation, an Ewing's sarcoma cell line forms cell junctions that resemble adherens junctions (30) . It is known that CDH1 down-regulation is critical for the formation of adherens junctions and gastric carcinogenesis (7). Thus, it is possible that CD99 signaling is involved in epithelial cell-epithelial cell adhesion, similarly to CDH1.
With regard to gastric carcinoma progression, the loss of CD99 expression can be considered as a later event, supporting the suggestion that gastric carcinoma cells arise not from metaplastic cells but from gastric cells and then lose their identity as tumor progression (31) . First, the loss of CD99 expression was also observed in intestinal metaplasias of complete type, in which the gastric cell identity was lost, through the gastritis-dysplasia-carcinoma sequence, suggesting that the intestinal metaplasia should be recognized as a paraneoplastic phenomenon (31) . Second, this late event may be responsible for the loss of intercellular adhesion capability. CD99 down-regulation was clearly associated with increased direct tumor invasion and nodal metastasis. This agrees well with our previous clinicopathologic study for the loss of CD99 expression in gallbladder carcinomas (23) . Notably, the CD99-overexpressing AGS cell line showed reduced migration and proliferation, and CD99 knockdown in MKN74 increased migration. In accordance with, the forced expression of CD99 in the osteosarcoma cell lines significantly inhibited cell migration and abrogated their metastatic ability (32) . Third, it is possible that CD99 downregulation is related to the loss of cellular identity or differentiation. We found that loss of CD99 expression by tumor cells was clearly associated with their loss of cellular polarity and their failure to maintain a glandular structure in gastric carcinoma cases. It has also been shown that the CD99 down-regulation leads to the loss of normal morphology in Hodgkin's disease (13, 17) . Fourth, because the mouse CD99 orthologue has been found to specifically activate natural killer cells and dendritic cells by binding to PILRB (33, 34) , the loss of CD99 in gastric carcinoma may serve as an immune escape mechanism.
When the contributions of CD99 promoter methylation, CD99 LOH, and SP1 down-regulation to CD99 downregulation in gastric carcinoma were analyzed by using a logistic regression model, it was found that the CD99 downregulation can be explained much better by all three potential causes together than by just one. It was shown that CD99 promoter methylation and LOH specifically occur when CD99 is down-regulated. In contrast, whereas over half of the cancer cases with CD99 down-regulation had decreased expression of SP1, SP1 down-regulation was also observed in some CD99 + cases. To confirm the clinicopathologic study about the relationship between CD99 and SP1, we did CD99 promoter assay and verified that SP1 may be critical for CD99 promoter activity in several cancer cell lines. Furthermore, the combination of CD99 promoter methylation, CD99 LOH, and SP1 down-regulation can account for nearly 81% of the gastric cancer cases with CD99 down-regulation. It is likely that the remaining 19% of cases may be explained by additional mechanisms that lead to the loss of CD99 expression, such as mutations, posttranslational modifications, and additional derangements of other transcription factors. We also suggest that CD99 mutations could be responsible to some degree for CD99 down-regulation as the KATOIII cell line contains a point mutation or an unknown single nucleotide polymorphism in its 5 ¶ untranslated region and expresses little CD99 mRNA. It is possible that such CD99 alteration may decrease mRNA stability (Supplementary Materials and Methods; Supplementary Table S3 ).
In conclusion, this study revealed that loss of CD99 expression in gastric carcinoma is clearly associated with poor prognosis and unfavorable clinicopathologic variables. Most of the cases with loss of CD99 expression can be explained by a combination of loss of SP1 expression, LOH of the CD99 gene locus, and methylation of the CD99 promoter region. We also showed that CD99 down-regulation was associated with proliferation and migration in gastric carcinoma cell line. These observations suggest that the loss of CD99 expression is a critical event in gastric carcinoma progression.
